PMID- 38348001
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240214
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 16
IP  - 1
DP  - 2024 Jan
TI  - Observational, Multicenter, Retrospective, Study on the Usage Patterns of the 
      Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 
      Diabetes Management.
PG  - e52064
LID - 10.7759/cureus.52064 [doi]
LID - e52064
AB  - Objective This study aimed to evaluate and analyze the characteristics of Indian 
      patients with type 2 diabetes mellitus (T2DM) in relation to the usage patterns 
      of a fixed-dose combination (FDC) of glimepiride, metformin, and voglibose. 
      Methods This retrospective, observational, multicentric analysis was conducted 
      from March 2021 to September 2022. It involved adult patients (aged >/=18 years) 
      with T2DM from 424 sites including a combination of hospitals and privately owned 
      clinics across India to ensure comprehensive representation of the patient 
      population The study included patients who had been treated with FDC of 
      glimepiride, metformin, and voglibose of varying strengths for T2DM management. 
      Data were collected through a pre-designed electronic form, which captured 
      demographic details, medical history, T2DM history, and drug usage patterns from 
      medical records. The collected data were then analyzed using descriptive 
      statistical methods. Results This analysis encompassed a final cohort of 8,587 
      patients out of which 5,840 were males with a mean age of 54.91 years and a BMI 
      of 28.41 kg/m(2). Newly diagnosed T2DM cases were 35.23%, 54.79% had a family 
      history, and 61.21% had risk factors such as smoking, sedentary lifestyle, and 
      others. Dyslipidemia (13.94%) and neuropathy (14.48%) were common comorbidities. 
      The most prescribed FDC was 1 mg glimepiride, 500 mg metformin, 0.2 mg voglibose 
      (40.14%), the most preferred dosing frequency was once daily (52.92%) and the 
      most common duration of treatment was one to three months (48.78%). Conclusion In 
      routine Indian clinical practice, the triple drug FDC of 1 mg glimepiride, 500 mg 
      metformin, and 0.2 mg voglibose, taken once daily for one to three months, was 
      the most common treatment for both newly diagnosed and long-standing diabetes 
      patients.
CI  - Copyright (c) 2024, Shamanna et al.
FAU - Shamanna, Paramesh
AU  - Shamanna P
AD  - Department of Diabetes and Endocrinology, Bangalore Diabetes Centre, Bangalore, 
      IND.
FAU - Jha, Pankaj Kumar
AU  - Jha PK
AD  - Department of Medical Services, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
FAU - Makwana, Altaf
AU  - Makwana A
AD  - Department of Medical Services, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
FAU - Shukla, Heta
AU  - Shukla H
AD  - Department of Medical Services, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
FAU - Bavishi, Chintan
AU  - Bavishi C
AD  - Department of Medical Services, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
LA  - eng
PT  - Journal Article
DEP - 20240110
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10859676
OTO - NOTNLM
OT  - fixed dose combination
OT  - glimepiride
OT  - metformin
OT  - observational study
OT  - usage pattern
OT  - voglibose
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2024/02/13 06:44
MHDA- 2024/02/13 06:45
PMCR- 2024/01/10
CRDT- 2024/02/13 03:38
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/13 06:45 [medline]
PHST- 2024/02/13 06:44 [pubmed]
PHST- 2024/02/13 03:38 [entrez]
PHST- 2024/01/10 00:00 [pmc-release]
AID - 10.7759/cureus.52064 [doi]
PST - epublish
SO  - Cureus. 2024 Jan 10;16(1):e52064. doi: 10.7759/cureus.52064. eCollection 2024 
      Jan.